Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Events & Conferences | Wed 04, 2024
Bottneuro at the BOOM Summit 2024
Bottneuro is excited for two healthtech-filled days at BOOM Summit 2024 in Basel, Switzerland.
Business Update | Wed 04, 2024
European patent granted
Bottneuro AG has been granted an important patent!
Featured | Tue 04, 2024
Bottneuro's Miamind Neurostimulator Spotlighted in Uni Basel Article
Bottneuro's Miamind® Neurostimulator has been featured in an article published by the University of Basel.
Events & Conferences | Mon 03, 2024
Bottneuro at the LSIUSA24
Alois Hopf, CSO of Bottneuro, is representing Bottneuro AG at the LSIUSA24 in Dana Point, California.
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
